Compare TNXP & ANGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | ANGI |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 180.9M |
| IPO Year | 2008 | 2017 |
| Metric | TNXP | ANGI |
|---|---|---|
| Price | $13.32 | $4.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 486.9K | ★ 871.9K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.75 | ★ 1242.86 |
| EPS | ★ N/A | N/A |
| Revenue | $13,107,000.00 | ★ $736,386,000.00 |
| Revenue This Year | $558.11 | $3.25 |
| Revenue Next Year | $38.29 | $3.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 29.85 | ★ 47.60 |
| 52 Week Low | $9.40 | $4.26 |
| 52 Week High | $29.19 | $18.70 |
| Indicator | TNXP | ANGI |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 49.86 |
| Support Level | $11.98 | $4.74 |
| Resistance Level | $13.36 | $6.52 |
| Average True Range (ATR) | 0.71 | 0.30 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 52.17 | 69.40 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.